Table 1 Comparison of baseline characteristics
| Â | Sorafenib (NCT01761266) | Lenvatinib (NCT01761266) | Atezolizumab- Bevacizumab (NCT03434379) | Sintilimab-Bevacizumab (NCT03794440) | ||||
|---|---|---|---|---|---|---|---|---|
N | % | N | % | N | % | N | % | |
Number of patients | 476 | 100 | 478 | 100 | 336 | 100 | 380 | 100 |
Age (mean) | 64 | Â | 63 | Â | 64 | Â | 53 | Â |
Males | 401 | 84 | 405 | 85 | 227 | 82 | 334 | 88 |
Females | 75 | 16 | 73 | 15 | 109 | 18 | 46 | 12 |
HBV infection | 228 | 48 | 251 | 53 | 164 | 49 | 359 | 94 |
HCV infection | 126 | 27 | 91 | 19 | 72 | 21 | 6 | 2 |
Child–Pugh stage | ||||||||
 A | 357 | 75 | 368 | 77 | 239 | 72 | 365 | 96 |
 B | 119 | 25 | 110 | 23 | 94 | 28 | 15 | 4 |
BCLC stage | ||||||||
 B | 92 | 19 | 104 | 22 | 52 | 15 | 56 | 15 |
 C | 384 | 81 | 374 | 78 | 276 | 82 | 324 | 85 |
Presence of macrovascular invasion, extrahepatic metastasis | 430 | 90 | 441 | 92 | 258 | 77 | 303 | 80 |